Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

FDA broadens label for Amgen's Uplizna as it enters rare disease competition

Summary by endpoints.news
The FDA on Thursday expanded the label for Amgen’s rare disease drug Uplizna, approving it in an autoimmune disorder that’s quickly become a hot — and crowded — area for biopharma. Regulators gave the green light to ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

endpoints.newsendpoints.news

FDA broadens label for Amgen's Uplizna as it enters rare disease competition

The FDA on Thursday expanded the label for Amgen’s rare disease drug Uplizna, approving it in an autoimmune disorder that’s quickly become a hot — and crowded — area for biopharma. Regulators gave the green light to ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Friday, December 12, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Amgen icon

Amgen

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal